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LBP treatment rates. Wilcoxon signed-rank tests were used to compare study period 
direct (medical and drug) costs from third-party payer perspective. RESULTS: During
the 6-month study period, duloxetine-treated patients vs. controls had signiﬁ cantly 
lower rates of other pharmacological therapy (34.2% vs. 43.4% narcotic opioids, p
 0.004; 30.4% vs. 43.2% NSAIDs, p  0.001; 17.4% vs. 26.2% muscle relaxants, 
p  0.001; 10.6% vs. 20.4% corticosteroids, p  0.001) and non-invasive therapy
(16.4% vs. 35.6% chiropractic therapy, p  0.001; 13.0% vs. 34.2% physical therapy,
p  0.001). Duloxetine-treated patients were also signiﬁ cantly less likely to have a 
back surgery during the study period compared with controls (0.4% vs. 2.0%, respec-
tively; p  0.021). Average 6-month direct costs were not signiﬁ cantly different
between duloxetine-treated patients and controls ($3554 vs. $3637, respectively). 
CONCLUSIONS: Duloxetine treatment in LBP patients vs. other non-surgical treat-
ment was associated with a lower surgery rate as well as reduced rates of other non-
surgical therapies without signiﬁ cant differences in direct costs.
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OBJECTIVES: Hemophilia is a costly chronic illness. Clotting factor accounts for over 
70% of hemophilia costs. We examined health care utilization, factor use and costs
in people with hemophilia A from six Hemophilia Treatment Centers in seven states.
METHODS: Data were obtained prospectively from interviews and chart reviews with 
329 patients aged 2 to 65 years enrolled in the Hemophilia Utilization Group Study
Part V-A(2005–2007). We analyzed one-year health care utilization (outpatient, emer-
gency room visits, and hospitalization) and total cost of clotting factor dispensed. 
Factor cost was estimated using average sales price from Medicare Part B. We further 
examined the association between these variables and clotting factor infusion strate-
gies (episodic(to treat a bleed) versus prophylactic (administrate multiple times each
week)) in patients with severe hemophilia using Chi-square test for categorical vari-
ables or Wilcoxon rank-sum test for continuous variables. RESULTS: Fifty percent of 
patients were adults; Mean age 9.7 o 4.5 years for children and 33.7 o 12.5 years for 
adults. Two-thirds of patients had severe hemophilia. 97% used clotting factor; 68% 
of severe patients infused prophylactically. 89% reported using health services at least
once: 56% had a comprehensive visit(range:0–3); 31% a clinician visit(range:0–14);
23% saw a physical therapist(range:0–21). 19% had emergency room visits and 15% 
were hospitalized. Mean cost of clotting factor was $208,548(median:$232,831) per
patient-year. In patients with severe hemophilia, average number of hospital days/
patient-year was 8(3 for prophylaxis users versus 13 for episodic treatment users, p
 0.14). Patients with severe hemophilia were less likely to have an emergency room 
visit if they were on prophylaxis(13% vs. 25%, p  0.047). Mean factor cost was
$281,151 per patient-year(median:$224,856) for patients on prophylaxis versus $15
4,855(median:$126,148) for episodic treatment users(p  0.0001). CONCLUSIONS:
This study contributes to the growing evidence that prophylactic infusion of clotting
factors, compared to episodic treatment, may be associated with decreased health care
utilization, including emergency room visits and hospitalizations.
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OBJECTIVES: To describe and measure intravenous patient controlled analgesia (IV-
PCA) processes in postoperative pain management in patients with moderate to severe
pain in clinical practice that have undergone surgery at the University Hospital Oulu
Finland. METHODS: A model was designed and visualized via Swimlane notation. 
Sub process levels were deﬁ ned as “education”, “purchasing/depreciation/mainte-
nance”, “procurement”, “supply”, “application” and “disposal”. Based on these sub
process levels, data was collected by two research methods, interviews and measure-
ment forms including patient and staff satisfaction questionnaires. RESULTS: Twelve
members of Oulu University Hospital personnel with different responsibilities were 
interviewed to deﬁ ne the roles and activities involved in the entire IV-PCA process. 
Ten different roles were deﬁ ned with 151 different activities. The involved roles and
the duration of each activity in the sub process levels “supply”, “application” and
“disposal” were measured from 108 consecutive patients with eight different surgery 
types. The most common surgery types were back surgery and gynecological laparos-
copy. The average duration of IV-PCA use per patient was 41 hours and 39 minutes. 
The staff spent on average 132 minutes in IV-PCA related activities, of which the nurse
spent 91%. The average cost, including material and staff, for 24-hour usage of IV-
PCA was €122. The patients found the IV-PCA system easy to operate but hindered 
them in mobility and they were not able to sleep unhindered. According to the staff 
the IV-PCA system operated error-free and reliably but hindered the mobilization of 
the patient. CONCLUSIONS: IV-PCA involves many different roles and activities and 
intertwined sub processes. Therefore the whole system is complex and resource
demanding. Comparisons of the results from similar studies at other hospitals will be 
very useful when trying to optimize the process.
SYSTEMIC DISORDERS/CONDITIONS – Patient-Reported
Outcomes Studies
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OBJECTIVES: To examine the impact of obesity on health-related quality of life
(HRQOL) in patients with asthma. METHODS: The data used for the present study 
was obtained from the 2004–2006 Medical Expenditure Panel Survey (MEPS) data, 
a comprehensive national representative survey of the U.S. non-institutionalized popu-
lation. Individuals were included if they were aged 18–74, self report of diagnosed
with asthma or diagnosed with ICD-9 code of 493 by their physician, and did not 
have pregnancy, malignancy, kidney dialysis, or immunodeﬁ ciency. Asthma patients 
were classiﬁ ed as normal (body mass index(BMI):18.5-25), or obese(BMI:q30). 
MEPS measured HRQOL using SF-12 physical component scale (PCS-12), SF-12
mental component scale (MCS-12), Kessler Index (K-6), and Patient Health Question-
naire (PHQ2). The K-6 assesses the person’s non-speciﬁ c psychological distress (higher 
value means severe mental disability) and the PHQ2 assesses the depression severity.
PHQ2 score of q3 was used to screen asthma patient with depression. The impact of 
obesity on HRQOL was estimated using multivariable regression while controlling for 
patients’ demographic, socio-economic, and co-morbidity variables. Data were ana-
lyzed using SAS and STATA. RESULTS: A total of 5339 asthma patients were identi-
ﬁ ed. Overall, HRQOL in obese patients were signiﬁ cantly lower compared to those 
of normal weight patients (50.7 vs. 41.9 for PCS-12, 49.0 vs. 47.0 for MCS-12, 3.9 
vs. 5.3 for K-6, 0.6 vs. 1.1 for PHQ-2). While controlling for the study variables, QOL
were worse if patients were obese, older, female, or less educated, as well as have car-
diovascular disease. Proportion of patients with PHQ2 score q3 were 10.3% in normal 
weight and 19.7% in obese patients. CONCLUSIONS: Obesity signiﬁ cantly deterio-
rates quality of life including both physical and mental components in asthma patients.
The national health promotion to control weight needs to be emphasized to increase 
the beneﬁ cial effects of HRQL in asthma patients.
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OBJECTIVES: Patients with failed back surgery syndrome (FBSS) and chronic neuro-
pathic pain experience levels of health-related quality of life (HRQoL) that are con-
siderably lower than those reported in other areas of chronic pain. Interventions aimed 
at reducing pain in FBSS patients are expected to bring considerable HRQoL improve-
ments. Using data from the multinational PROCESS trial, we investigated the longi-
tudinal relationship between generic HRQoL – assessed using two instruments often 
used in clinical trials (i.e. the SF36 and EuroQol5D) – and disease speciﬁ c outcome
measures (i.e. Oswestry Disability Index [ODI], leg and back pain visual analogue 
scale [VAS]) in neuropathic patients with FBSS. METHODS: Multivariate hierarchical 
regression models to capture the longitudinal trend in the dependent variables (i.e.
generic HRQoL), and to assess their relationship with patient baseline variables and 
clinical history. RESULTS: Generic HRQoL was univariately consistently associated
with disease speciﬁ c outcome measures: ODI (correlation coefﬁ cient: 0.462 to 
0.638) and leg pain VAS (correlation coefﬁ cient: 0.165 to 0.436). In multilevel 
regression analysis, baseline HRQoL and ODI were found to be signiﬁ cant predictors 
of generic HRQoL (all p  0.001). Leg pain was predictive of EuroQol5D and the
SF36 physical component summary score (both p  0.001) but not of its mental com-
ponent summary score (p  0.201). Baseline socio demographic characteristics (age
and gender), clinical history (time since last back surgery and number of back surger-
ies), location of pain and intensity of back pain were not predictive of generic HRQoL
(all p  0.10). CONCLUSIONS: Reduction in leg pain and functional disability is 
statistically signiﬁ cantly associated with improvements in generic HRQoL. This is the 
ﬁ rst study to investigate the longitudinal relationship between generic and disease 
speciﬁ c HRQoL of neuropathic pain patients with FBSS, using multinational data.
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Patients with neuropathic pain (NeuP) report poorer health-related quality of life
(HRQoL) and incur higher health care costs than non neuropathic pain patients. 
Although the impact of NeuP on HRQoL has been the subject of previous reviews,
